Microbiome medicine accelerated by new partnership between BiomeBank and Hudson Institute

BiomeBank
  • BiomeBank and Hudson Institute sign a 4-year collaboration agreement to discover and develop microbial therapies.
  • BiomeBank gains exclusive license to paediatric IBD study, which identified key bacteria believed to be involved in disease onset and resolution. These bacteria were identified using a world-first method that unlocks culturing and metagenomics of colon biopsy samples.
  • January 27, 2022. The translation of research into the development of innovative and life-saving microbial therapies is set to transform in Australia through a partnership between Hudson Institute of Medical Research and BiomeBank, a clinical stage microbiome therapeutics company.

    A Memorandum of Understanding between the two organisations has been signed, enabling BiomeBank to bring its experience in the discovery and development of microbial therapies to enable translation of Hudson Institute’s microbiome research.

    The partnership strengthens Hudson Institute’s business case for an Australian-first National Centre for Inflammation Research (“NCIR”) and will initially focus on the development of defined and targeted microbial therapies to treat unmet medical need for patients with Inflammatory Bowel Disease (“IBD”).

    BiomeBank, which has recently launched its Series-A funding round, has signed a four-year collaborative agreement with Hudson Institute to translate current and future microbiome research into microbial therapies. This includes a recent deal granting BiomeBank access to important research on how the microbiota could treat paediatric IBD, which is unique because the research used culturing and high-resolution microbial analysis of the colon rather than stool samples.

    BiomeBank CEO, Mr Thomas Mitchell said: “The combined strengths of the two organisations will put the new partnership at the forefront of the discovery and development of defined and targeted microbial therapies.

    “Together with Hudson Institute and along with its plans to establish a world-class NCIR, we’ll work to identify the key microbial strains which play a role in IBD and combine our capabilities to develop a safe and effective microbial therapy for patients.

    “This partnership places Australia firmly on the map as a world-leader in the development of a new class of therapies to treat unmet medical need across the globe.”

    Hudson Institute Director and CEO, Professor Elizabeth Hartland added that: “The partnership between Hudson Institute and BiomeBank is a critical first step in translating our microbiome discoveries and developing a new generation of treatments for patients.”

    Leading microbiome researcher from Hudson Institute, Dr Samuel Forster said: “The partnership will place Australia at the forefront of microbial research and drug discovery.

    “Through our work at Hudson Institute, we have developed new ways to isolate human bacteria, resulting in one of the most diverse collections of human commensal bacteria in the world and a detailed understanding of how these may protect against disease.

    “Modifying the microbiome as a treatment represents a new way of doing medicine. Working with BiomeBank will provide the opportunity to apply our cutting-edge discoveries to improve patients’ lives.”

    /Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).